CY1112337T1 - Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου - Google Patents

Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου

Info

Publication number
CY1112337T1
CY1112337T1 CY20111100570T CY111100570T CY1112337T1 CY 1112337 T1 CY1112337 T1 CY 1112337T1 CY 20111100570 T CY20111100570 T CY 20111100570T CY 111100570 T CY111100570 T CY 111100570T CY 1112337 T1 CY1112337 T1 CY 1112337T1
Authority
CY
Cyprus
Prior art keywords
sulfonamido
acetamide
amyloid peptide
inhibitor
production
Prior art date
Application number
CY20111100570T
Other languages
English (en)
Inventor
Jr John E Starrett
Kevin W Gillman
Richard E Olson
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112337(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1112337T1 publication Critical patent/CY1112337T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει καινοφανή ένωση άλφα-(Ν-σουλφοναμιδο)ακεταμιδίου, την φαρμακευτική σύνθεση αυτής, τις διεργασίες εξ αυτής και μέθοδο για την αγωγή της νόσου του Αλτσχάιμερ και άλλων καταστάσεων που συσχετίζονται με το β-αμυλοειδές πεπτίδιο.
CY20111100570T 2007-10-31 2011-06-15 Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου CY1112337T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31
EP08843687A EP2205575B1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Publications (1)

Publication Number Publication Date
CY1112337T1 true CY1112337T1 (el) 2015-12-09

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100570T CY1112337T1 (el) 2007-10-31 2011-06-15 Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου
CY20121100889T CY1113346T1 (el) 2007-10-31 2012-09-28 Καινοφανη ενδιαμεσα προϊοντα χρησιμα στην παρασκευη της ενωσης του αλφα-(ν-σουλφοναμιδο)ακεταμιδιου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100889T CY1113346T1 (el) 2007-10-31 2012-09-28 Καινοφανη ενδιαμεσα προϊοντα χρησιμα στην παρασκευη της ενωσης του αλφα-(ν-σουλφοναμιδο)ακεταμιδιου

Country Status (29)

Country Link
US (2) US8084477B2 (el)
EP (3) EP2471769A1 (el)
JP (1) JP5460605B2 (el)
KR (1) KR20100075575A (el)
CN (2) CN102718689A (el)
AR (1) AR069135A1 (el)
AT (1) ATE502022T1 (el)
AU (1) AU2008319122A1 (el)
BR (1) BRPI0818837A2 (el)
CA (1) CA2704360A1 (el)
CL (1) CL2008003271A1 (el)
CO (1) CO6270332A2 (el)
CY (2) CY1112337T1 (el)
DE (1) DE602008005636D1 (el)
DK (2) DK2295417T3 (el)
EA (2) EA201171439A1 (el)
ES (2) ES2361283T3 (el)
HK (2) HK1141801A1 (el)
HR (2) HRP20110219T1 (el)
IL (1) IL205406A0 (el)
MX (1) MX2010004319A (el)
NZ (1) NZ584545A (el)
PE (1) PE20091394A1 (el)
PL (2) PL2205575T3 (el)
PT (2) PT2205575E (el)
SG (2) SG174043A1 (el)
SI (2) SI2205575T1 (el)
TW (1) TW200927099A (el)
WO (1) WO2009058552A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1465861T1 (sl) 2001-12-20 2009-12-31 Bristol Myers Squibb Co Alfa-(n-sulfonamido)acetamidni derivati kot beta-amiloid inhibitorji
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
NZ594561A (en) * 2009-03-19 2013-03-28 Bristol Myers Squibb Co A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
AU2011225122B8 (en) * 2010-03-12 2013-12-12 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
US9284296B2 (en) 2010-11-22 2016-03-15 Aubergine Pharmaceuticals Llc Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
US9249157B2 (en) 2012-09-21 2016-02-02 Bristol-Myers Squibb Company Tricyclic heterocycle compounds
US9133139B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
EP2897944B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
EP2897938B1 (en) 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
RU2757276C2 (ru) 2016-12-16 2021-10-12 Пайплайн Терапьютикс, Инк. Способы лечения кохлеарной синаптопатии
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
WO2020261093A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
PL326700A1 (en) * 1995-11-17 1998-10-26 Warner Lambert Co Sulphonamide-based inhibitors of intercellular substance metaloproteinases
CZ16899A3 (cs) 1996-07-22 1999-08-11 Monsanto Company Thiolsulfonamidové inhibitory metaloproteázy
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するTNF―α産生抑制剤
HUP0105282A3 (en) 1999-01-27 2005-04-28 Wyeth Holdings Corp Madison Acetylenic sulfonamide thiol tace inhibitors process for their preparation and pharmaceutical compositions containing the same
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
MXPA01008606A (es) 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
DE60239078D1 (de) * 2001-12-14 2011-03-10 Raytheon Co Präzise justierte linsenstruktur und eine methode zur herstellung derselben
SI1465861T1 (sl) * 2001-12-20 2009-12-31 Bristol Myers Squibb Co Alfa-(n-sulfonamido)acetamidni derivati kot beta-amiloid inhibitorji
KR20040086465A (ko) * 2002-02-28 2004-10-08 아스트라제네카 아베 화합물
DE60313844T2 (de) * 2003-03-20 2008-01-31 Santhera Pharmaceuticals (Schweiz) Ag Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
NZ542468A (en) * 2003-03-31 2009-01-31 Wyeth Corp Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US7144894B2 (en) * 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
EP1984347A1 (en) * 2006-02-17 2008-10-29 Wyeth a Corporation of the State of Delaware Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
AR059518A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp Metodos para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
PL2205575T3 (pl) 2011-09-30
HK1155161A1 (en) 2012-05-11
BRPI0818837A2 (pt) 2015-04-22
HRP20120703T1 (hr) 2012-09-30
EP2471769A1 (en) 2012-07-04
EA201171439A1 (ru) 2012-05-30
US8084477B2 (en) 2011-12-27
SI2295417T1 (sl) 2012-11-30
US20090111858A1 (en) 2009-04-30
AU2008319122A1 (en) 2009-05-07
MX2010004319A (es) 2010-04-30
SG174043A1 (en) 2011-09-29
SI2205575T1 (sl) 2011-07-29
ES2361283T3 (es) 2011-06-15
JP5460605B2 (ja) 2014-04-02
CL2008003271A1 (es) 2009-07-10
ATE502022T1 (de) 2011-04-15
JP2011502153A (ja) 2011-01-20
HRP20110219T1 (hr) 2011-04-30
TW200927099A (en) 2009-07-01
PT2205575E (pt) 2011-05-23
ES2390042T3 (es) 2012-11-06
DK2205575T3 (da) 2011-07-11
US8350084B2 (en) 2013-01-08
CO6270332A2 (es) 2011-04-20
US20120088925A1 (en) 2012-04-12
CN101910141B (zh) 2012-12-19
PE20091394A1 (es) 2009-09-25
AR069135A1 (es) 2009-12-30
EP2205575A1 (en) 2010-07-14
EA016447B1 (ru) 2012-05-30
SG174044A1 (en) 2011-09-29
CN102718689A (zh) 2012-10-10
DK2295417T3 (da) 2012-10-15
KR20100075575A (ko) 2010-07-02
CY1113346T1 (el) 2016-06-22
DE602008005636D1 (de) 2011-04-28
EP2295417B1 (en) 2012-07-04
EP2205575B1 (en) 2011-03-16
PT2295417E (pt) 2012-09-26
NZ584545A (en) 2011-04-29
HK1141801A1 (en) 2010-11-19
EP2295417A1 (en) 2011-03-16
CN101910141A (zh) 2010-12-08
PL2295417T3 (pl) 2012-11-30
WO2009058552A1 (en) 2009-05-07
IL205406A0 (en) 2010-12-30
EA201000714A1 (ru) 2010-10-29
CA2704360A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CY1112337T1 (el) Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου
CY1122861T1 (el) Φαρμακευτικες συνθεσεις της αμορφης μορφης ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου
AR077016A1 (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
CY1117934T1 (el) Αντιβακτηριακες φαρμακευτικες συνθεσεις
CL2010001368A1 (es) Compuestos derivados de 1,3-tiazina; composicion farmaceutica que lo comprende; utiles para inhibir a la beta-secretasa
NO20083598L (no) Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase
GT200600432A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la beta-secretasa
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
CY1119077T1 (el) Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
CY1120846T1 (el) 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
BRPI0915692B8 (pt) compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos
MA31564B1 (fr) Inhibition par arni de l'expression du canal alpha-enac
BR0215182A (pt) Derivados de (alfa)- (n-sulfonamido) acetamida como inibidores de (beta)-amilóide
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
EA201291413A1 (ru) Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
AR050717A1 (es) Composiciones farmaceuticas
BRPI0607330A2 (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
GT201000045A (es) Derivados de ciclopropilamida '978